Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RIFAMPIN vs RIFAXIMIN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RIFAMPIN vs RIFAXIMIN: Safety Overview

Metric RIFAMPIN RIFAXIMIN
Total FAERS Reports 13,347 13,861
Deaths Reported 1,439 5,009
Death Rate 10.8% 36.1%
Hospitalizations 5,764 4,847
Average Patient Age 51.7 yrs 63.2 yrs
% Female Patients 47.8% 54.9%
FDA Approval Date Approved Prior to Jan 1, 1982 Mar 24, 2010
Manufacturer Hikma Pharmaceuticals USA Inc. Salix Pharmaceuticals, Inc.
Route INTRAVENOUS ORAL
Marketing Status Discontinued Prescription